RxDoctor Payments Data

Jasjeet Khural

Cardiovascular Disease · Matthews, NCNPI 1922492909

Payments from drug & device makers

$1,177in general payments, 2019–2025

Across 41 payments — averaging $28.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$290
  • Kestra Medical Technology Services, Inc.$227
  • Novartis$219
  • Boston Scientific$191
  • E.r. Squibb & Sons, L.L.C.$97
  • Scpharmaceuticals Inc.$76
  • plus $76 from 3 others

What the payments were for

  • Food & beverage$1,177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,177 in reported general payments places this provider in the 35th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$130,610
Medicare patients
1,030
Services billed
2,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban324$303,964
XareltoRivaroxaban79$73,329
JardianceEmpagliflozin59$64,102
EntrestoSacubitril/Valsartan36$42,711
FarxigaDapagliflozin Propanediol25$14,236
Repatha SureclickEvolocumab14$8,563
Praluent PenAlirocumab12$5,962
Metoprolol Succinate337$3,199
Atorvastatin Calcium237$2,121
Ezetimibe108$2,078
Ranolazine ErRanolazine28$2,048
Flecainide Acetate46$1,612
Rosuvastatin Calcium125$1,300
Diltiazem 24hr Er (Cd)Diltiazem Hcl38$1,136
Amiodarone Hcl50$1,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$21$73,32979 claims
Boehringer IngelheimJardiance$29$64,10259 claims
NovartisEntresto$219$42,71136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →